Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 13/20 | 0.64 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.64 |
| ▸ | NPY1R | P25929 | 7/20 | 0.64 |
| ▸ | NPY2R | P49146 | 5/20 | 0.64 |
| ▸ | NMUR2 | Q9GZQ4 | 3/20 | 0.63 |
| ▸ | NMUR1 | Q9HB89 | 3/20 | 0.63 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.56 |
| ▸ | TFPI | P10646 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10078742 | 0.87 | NMUR2 (0.68) | NPY4RNPY5RNPY1RNPY2RNMUR2 | |
| SCHEMBL12697275 | 0.81 | NMUR2 (0.61) | NPY4RNPY5RNPY1RNPY2RNMUR2 | |
| SCHEMBL17226117 | 0.81 | NMUR2 (0.58) | NPY4RNPY5RNPY1RNPY2RNMUR2 | |
| SCHEMBL2632668 | 0.80 | NMUR2 (0.73) | NMUR2NMUR1 | |
| SCHEMBL10079188 | 0.79 | NMUR2 (0.70) | NPY4RNPY5RNPY1RNPY2RNMUR2 | |
| SCHEMBL10078439 | 0.79 | NMUR2 (0.56) | NPY4RNPY5RNPY1RNPY2RNMUR2 | |
| SCHEMBL17226128 | 0.78 | NMUR2 (0.66) | NPY4RNPY5RNPY1RNPY2RNMUR2 | |
| SCHEMBL6470874 | 0.77 | NPY4R (0.72) | NPY4RNPY5RNPY1RNPY2RKISS1R | |
| SCHEMBL6470860 | 0.77 | NPY4R (0.72) | NPY4RNPY5RNPY1RNPY2RKISS1R | |
| SCHEMBL31141457 | 0.77 | TFPI (0.70) | NPY4RNPY5RNPY1RNPY2RKISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120094898-A1 | PEPTIDE DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094898-A1 | PEPTIDE DERIVATIVE | NPPA, LNPEP, NGLY1 | NPY4R 188/4885NPY5R 322/4885NPY1R 411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.